Early drug and anti骾nfliximab antibody levels for prediction of primary nonresponse to infliximab therapy
H Bar骙oseph, N Levhar, L Selinger… - Alimentary …, 2018 - Wiley Online Library
Background Primary nonresponse, defined as lack of clinical benefit during the induction
phase, occurs in up to 30% of IBD patients treated with infliximab. The mechanisms …
phase, occurs in up to 30% of IBD patients treated with infliximab. The mechanisms …
Early drug and anti骾nfliximab antibody levels for prediction of primary nonresponse to infliximab therapy
H Bar骙oseph, N Levhar, L Selinger, U Manor… - Alimentary …, 2017 - cir.nii.ac.jp
抄録< jats: title> Summary</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats:
p> Primary nonresponse, defined as lack of clinical benefit during the induction phase …
p> Primary nonresponse, defined as lack of clinical benefit during the induction phase …
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy
H Bar-Yoseph, N Levhar, L Selinger… - Alimentary …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Primary nonresponse, defined as lack of clinical benefit during the induction
phase, occurs in up to 30% of IBD patients treated with infliximab. The mechanisms …
phase, occurs in up to 30% of IBD patients treated with infliximab. The mechanisms …
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.
H Bar骙oseph, N Levhar, L Selinger… - Alimentary …, 2018 - search.ebscohost.com
Background Primary nonresponse, defined as lack of clinical benefit during the induction
phase, occurs in up to 30% of IBD patients treated with infliximab. The mechanisms …
phase, occurs in up to 30% of IBD patients treated with infliximab. The mechanisms …
[PDF][PDF] Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy
H Bar-Yoseph, N Levhar, L Selinger, U Manor… - researchgate.net
Background: Primary nonresponse, defined as lack of clinical benefit during the induction
phase, occurs in up to 30% of IBD patients treated with infliximab. The mechanisms …
phase, occurs in up to 30% of IBD patients treated with infliximab. The mechanisms …
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.
H Bar-Yoseph, N Levhar, L Selinger… - Alimentary …, 2017 - europepmc.org
BACKGROUND: Primary nonresponse, defined as lack of clinical benefit during the
induction phase, occurs in up to 30% of IBD patients treated with infliximab. The …
induction phase, occurs in up to 30% of IBD patients treated with infliximab. The …